Shape Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy 28th Annual MeetingData support potential of innovative gene therapy using novel RNA editing, paired with targeted AAV.ai delivery and scalable manufacturing platforms
Shape Therapeutics Unveils Major Advances in AI-Powered Platform for Precision RNA EditingCompany's DeepREAD AI model and small RNA expression system represent major leaps forward in RNA editing efficiency and specificity
Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of DirectorsEpstein and Simpson bring significant life sciences industry expertise that will be integral to the Company’s continued growth as a leader in AI for genomic medicine
Shape Therapeutics Announces Appointment of Matt Valentino as Chief People OfficerSEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the appointment of Matt Valentino as Chief People Officer.
Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today announced its upcoming oral presentations at the 27th American Society for Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 7-11 in Baltimore, MD. The Company’s featured presentations will highlight new data from their RNAfix® and TruStableTM platforms, demonstrating significant advancements in AAV-delivered RNA therapies.
ShapeTX Expands Strategic Collaboration with Roche with Addition of a New TargetSEATTLE, Nov. 30, 2023 (GLOBE NEWSWIRE) -- ShapeTX announced today the expansion of its partnership with Roche, with Roche adding a new target to their ongoing collaboration, which was initially established in August 2021. This expansion marks the beginning of a new program where ShapeTX will use its proprietary AI-powered RNA editing platform to develop a potential one-time therapy for patients with high unmet needs for an undisclosed disease affecting millions of people worldwide.
ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and BeyondSEATTLE, May 04, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced seven presentations from across its technology platforms to be featured at the 26th American Society for Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 16-20 in Los Angeles, CA. The featured presentations include new data from the company’s RNAfix®, RNAswap™, AAVid™, and TruStable™ platforms.
ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare ConferenceSEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare Conference, on January 9, 2023 at 3:00 p.m. Pacific Time. The presentation will highlight recent achievements across the ShapeTX technology platforms, including breakthrough results from ShapeTX's AI-driven AAVid™ capsid discovery platform and TruStable™ AAV manufacturing technology platform.
